[1]
Kaushik, A.; Wagner, C.; Consoer, H.; Chatterjee, A. Strategies for prevention of methicillin resistant staphylococcus aureus (MRSA) infections and decolonization. S. D. Med., 2016, 69(12), 535-539.
[2]
Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; Raybak, M.; Talan, D.A.; Chambers, H.F. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis., 2011, 52(3), 285-292.
[3]
Finch, R.G.; Eliopoulos, G.M. Safety and efficacy of glycopeptide
antibiotics. J. Antimicrob. Chemother., 2005, 55(SUPPL_2), ii5-
ii13.
[4]
Darley, E.S.; Macgowan, A.P. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin. Microbiol. Infect., 2004, 10(1), 62-69.
[5]
Boulamery, A.; Venisse, N.; Le, G.C. Level of evidence for therapeutic drug monitoring of teicoplatin. Therapie, 2011, 66(1), 45-50.
[6]
Begg, E.J.; Barclay, M.L.; Kirkpatric, C.M. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol., 1999, 47(1), 35-43.
[7]
Ye, Z.K.; Tang, H.L.; Zhai, S.D. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One, 2013, 8(10), e77169.
[8]
Gould, I.M.; Cauda, R.; Esposito, S.; Gudiot, F.; Mazzei, T.; Garau, J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob. Agents, 2011, 37(3), 202-209.
[9]
Macgowan, A.; Lovering, A.; White, L.; Reeves, D.; Collyns, T.A.; Oppenheim, B.A.; Wysocki, M.; Thomas, F.; Wolff, M.; Hoog, M.D.; Mouton, J.W.; Anker, J.N.; Duffull, S.B.; Begg, E.; Saunders, N. Why monitor peak vancomycin concentrations? Lancet, 2016, 345(8950), 646-647.
[10]
Tobin, C.M.; Lovering, A.M.; Sweeney, E.; Macgowan, A.P. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J. Antimicrob. Chemother., 2010, 65(10), 2155-2157.
[11]
Rybak, M.J.; Bailey, E.M.; Reddy, V.N. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob. Agents Chemother., 1991, 35(8), 1586-1590.
[12]
Mccann, S.J.; White, L.O.; Keevil, B. Assay of teicoplanin serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay. J. Antimicrob. Chemother., 2002, 50(1), 107-110.
[13]
Mochizuki, N.; Ohno, K.; Shimamura, T.; Furukawa, H.; Todo, S.; Kishino, S. Quantitative determination of individual teicoplanin in components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2017, 847(2), 78-81.
[14]
Abushandi, K.H. Determination of vancomycin in human plasma using high- performance liquid chromatography with fluorescence detection. Anal. Bioanal. Chem., 2009, 395(2), 527-532.
[15]
Luksa, J.; Marusic, A. Rapid high-performance liquid chromatographic determination of vancomycin in human plasma. J. Chromatogr. B Biomed. Appl., 1995, 667(2), 277-281.
[16]
Zhang, T.; Watson, D.G.; Azike, C.; Tettey, J.N.A.; Stearns, A.T.; Binning, A.R.; Payne, C.J. Determination of vancomycin in serum by liquid chromatography-high resolution full scan mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 857(2), 352-356.
[17]
Fung, F.H.; Tang, J.C.; Hopkins, J.P.; Dutton, J.; Bailey, L.; Davison, A. Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method. Ann. Clin. Biochem., 2012, 49(Pt5), 475-481.
[18]
Smith, D.S.; Eremin, S.A. Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules. Anal. Bioanal. Chem., 2008, 391(5), 1499-1507.
[19]
Taylor, P.J.; Tai, C.H.; Franklin, M.E.; Pillans, P.I. The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs. Clin. Biochem., 2011, 44(1), 14-20.
[20]
Ye, Z.K.; Chen, Y.L.; Chen, K.; Zhang, X.L.; Du, G.H.; He, B.; Li, D.K.; Liu, Y.N.; Yang, K.H.; Zhang, Y.Y.; Zhai, S.D. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J. Antimicrob. Chemother., 2016, 71(11), 3020-3025.
[21]
Ye, Z.K.; Li, C.; Zhai, S.D. Guidelines for therapeutic drug monitoring of vancomycin: A systematic review. PLoS One, 2014, 9(6), e99044.
[22]
Kim, S.W. Is therapeutic drug monitoring of teicoplanin useful? Infect. Chemother., 2014, 46(1), 64-65.
[23]
Oda, K.; Kasada, T.; Yoshikawa, M.; Tanoue, M.; Yamashita, T.; Takeshita, Y. Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients. Ther. Drug Monit., 2014, 36(3), 401-405.
